Literature DB >> 443498

Prevalence of hepatitis B in 27 Michigan hemodialysis centers.

G H Mayor, M R Hourani, D S Greenbaum, M J Patterson.   

Abstract

A large epidemiological survey of inhospital chronic hemodialysis patients was conducted in 27 (93%) of the 29 dialysis centers in Michigan. Serum was collected from 699 patients on chronic maintenance hemodialysis for periods from one month to eight years. Hepatitis B surface antigen (HBsAg) was determined in all patients by radioimmunoassay and positive samples were confirmed by specific neutralization. Antibody against HBsAg (anti-HBs) was determined by radioimmunoassay in 110 HBsAg negative patients from six dialysis units with a high prevalence of hepatitis B. HBsAg was detected in 80 (11.4%) patients distributed among 21 (78%) of 27 dialysis units and anti-HBs in 34 (31%) patients from the selected dialysis units. The prevalence of HBsAg was related to duration of dialysis, number of blood transfusions, and to a history of bilateral nephrectomy, but not to age, sex, race, nor the underlying renal disease. Twenty-one (26%) of the 80 HBsAg positive patients had not been previously identified by the clinical laboratories of their institutions. Since preventive measures were not taken in the care of these inapparent carriers of HBsAg, they represent an unrecognized risk.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 443498      PMCID: PMC1618990          DOI: 10.2105/ajph.69.6.581

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  15 in total

1.  Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers.

Authors:  W Szmuness; A M Prince; G F Grady; M K Mann; R W Levine; E A Friedman; M J Jacobs; A Josephson; S Ribot; F L Shapiro; K H Stenzel; W N Suki; G Vyas
Journal:  JAMA       Date:  1974-02-25       Impact factor: 56.272

2.  Serological and epidemiological studies of hepatitis B in haemodialysis units.

Authors:  C P Pattison; J E Maynard; K R Berquist; H M Webster
Journal:  Lancet       Date:  1973-07       Impact factor: 79.321

3.  Menstrual blood as a vehicle of Australia-antigen transmission.

Authors:  S Mazzur
Journal:  Lancet       Date:  1973-04-07       Impact factor: 79.321

4.  Hepatitis-B antigen in saliva and semen.

Authors:  J Heathcote; C H Cameron; D S Dane
Journal:  Lancet       Date:  1974-01-19       Impact factor: 79.321

5.  Hepatitis in a maintenance hemodialysis unit.

Authors:  J B Eastwood; J R Curtis; A J Wing; H E de Wardener
Journal:  Ann Intern Med       Date:  1968-07       Impact factor: 25.391

6.  An epidemic of hepatitis in a chronic-hemodialysis unit. Australia antigen and differences in host response.

Authors:  W T London; M Di Figlia; A Sutnick; B S Blumberg
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

7.  Hemodialysis-associated hepatitis.

Authors:  R A Garibaldi; J N Forrest; J A Bryan; B F Hanson; W E Dismukes
Journal:  JAMA       Date:  1973-07-23       Impact factor: 56.272

8.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure.

Authors:  H J Alter; L B Seeff; P M Kaplan; V J McAuliffe; E C Wright; J L Gerin; R H Purcell; P V Holland; H J Zimmerman
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

9.  Transmission of hepatitis B virus infection by transfusion of frozen-deglycerolized red blood cells.

Authors:  H J Alter; E Tabor; H T Meryman; J H Hoofnagle; R A Kahn; P V Holland; R J Gerety; L F Barker
Journal:  N Engl J Med       Date:  1978-03-23       Impact factor: 91.245

10.  Hepatitis B surface antigen in urine of hemodialysis patients.

Authors:  M R Hourani; G H Mayor; D S Greenbaum; D O Hugget; M J Patterson
Journal:  Kidney Int       Date:  1978-04       Impact factor: 10.612

View more
  1 in total

1.  Cost without benefit? The introduction of hepatitis B vaccine in Canada.

Authors:  R A Coates; J G Rankin
Journal:  Can Med Assoc J       Date:  1983-05-15       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.